Pharmacologic Treatment in Dialysis Patients Hospitalized for Cardiovascular Reasons: Do We Follow the Guidelines?

REFERENCES

• Fox K, Garcia MA, Ardissino D, . Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J. 2006;27:1341–1381.
   PubMedGoogle Scholar
• K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(Suppl. 3):S1–S153.
   Google Scholar
• Lang RM, Bierig M, Devereux RB, . American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography; European Society of Cardiology. Recommendation for the chamber quantification. Eur J Echocardiography. 2006;7:79–108.
   PubMed Web of Science ®Google Scholar
• Judkins MP. Selective coronary arteriography: I: a percutaneous transfemoral technic. Radiology. 1967;89:815–824.
   PubMed Web of Science ®Google Scholar
• Alpert MA. Sudden cardiac arrest and sudden cardiac death on dialysis: epidemiology, evaluation, treatment, and prevention. Hemodial Int. 2011;15(Suppl. 1):S22–S29.
   Google Scholar
• Matsue Y, Suzuki M, Nagahori W, Ohno M, Matsumura A, Hashimoto Y. Beta-blocker prevents sudden cardiac death in patients with hemodialysis. Int J Cardiol. 2011.http://dx.doi.org/10.1016/j.ijcard.2011.09.037 [Epub ahead of print].
   Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G, . ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). ESC Committee for Practice Guidelines (CPG). Eur J Heart Fail. 2008;10:933–989.
   PubMed Web of Science ®Google Scholar
• Kitchlu A, Clemens K, Gomes T, . Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. Nephrol Dial Transplant. 2012;27:1591–1598.
   Google Scholar
• Rydén L, Standl E, Bartnik M, . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88–136.
   PubMed Web of Science ®Google Scholar
• Cravedi P, Remuzzi G, Ruggenenti P. Targeting the renin angiotensin system in dialysis patients. Semin Dial. 2011;24:290–297.
   PubMedGoogle Scholar
• Gamboa JL, Pretorius M, Todd-Tzanetos DR, . Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol. 2012;23:334–342.
   Google Scholar
• Tai DJ, Lim TW, James MT, Manns BJ, Tonelli M, Hemmelgarn BR. Alberta kidney disease network. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol. 2010;5:623–630.
   PubMed Web of Science ®Google Scholar
• Lin HH, Yang YF, Chang JK, . Renin–angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients. Ren Fail. 2009;31:942–945.
   PubMed Web of Science ®Google Scholar
• Krajina-Andricević M, Zibar L, Juras K, Goll-Barić S, Barbić J. Ramipril and risk of hyperkalemia in chronic hemodialysis patients. Coll Antropol. 2011;35:537–542.
   PubMedGoogle Scholar
• Scarpioni R, Ricardi M, Melfa L, Cristinelli L. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment? Cardiovasc Ther. 2010;28:361–368.
   PubMedGoogle Scholar
• Lee JE, Oh KH, Choi KH, . Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison. Nephrol Dial Transplant. 2011;26:4090–4094.
   PubMed Web of Science ®Google Scholar
• März W, Genser B, Drechsler C, . German diabetes and dialysis study investigators. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6:1316–1325.
   PubMedGoogle Scholar
• Wanner C, Krane V, Marz W, . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248.
   PubMed Web of Science ®Google Scholar
• Koc M, Dogan C, Arinsoy T, . Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodial Int. 2011;15:366–373.
   PubMed Web of Science ®Google Scholar
• Kirmizis D, Papagianni A, Dogrammatzi F, . Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. Atheroscler Thromb. 2010;17:1256–1265.
   Google Scholar
• Sezer MT, Katirci S, Demir M, Erturk J, Adana S, Kaya S. Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients. Scand J Urol Nephrol. 2007;41:436–441.
   PubMedGoogle Scholar
• Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagul Fibrinolysis. 2004;15:463–467.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Influence of simvastatin on aspects of thrombogenesis in CAPD patients. Perit Dial Int. 2003;23:260–266.
   PubMedGoogle Scholar
• Tsai TT, Maddox TM, Roe MT, . National cardiovascular data registry. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. J Am Med Assoc. 2009;302:2458–2464.
   PubMed Web of Science ®Google Scholar
• Hudson JQ, McNeely EB, Green CA, Jennings LK. Assessment of eptifibatide clearance by hemodialysis using an in vitro system. Blood Purif. 2010;30:266–271.
   PubMedGoogle Scholar
• Sperling RT, Pinto DS, Ho KK, Carrozza JP Jr. Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. Catheter Cardiovasc Interv. 2003;59:459–462.
   PubMedGoogle Scholar
• Davenport A. Optimization of heparin anticoagulation for hemodialysis. Hemodial Int. 2011;15(Suppl 1):S43–S48.
   Google Scholar
• Davenport A. Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient hemodialysis treatments. Nephrology (Carlton). 2009;14:455–461.
   PubMedGoogle Scholar
• Brophy DF, Carr ME Jr, Martin EJ, Venitz J, Gehr TW. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. J Clin Pharmacol. 2006;46:887–894.
   PubMedGoogle Scholar
• Wetmore JB, Mahnken JD, Mukhopadhyay P, . Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. Am J Kidney Dis. 2011;58:73–83.
   PubMedGoogle Scholar
• Giverhaug T, Bruland C, Trovik T. Secondary prevention in coronary heart disease: goal achievement and drug prescribing. Pharm World Sci. 2005;27:472–474.
   PubMedGoogle Scholar